These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 37853129)

  • 21. Multiple mechanisms for CRISPR-Cas inhibition by anti-CRISPR proteins.
    Bondy-Denomy J; Garcia B; Strum S; Du M; Rollins MF; Hidalgo-Reyes Y; Wiedenheft B; Maxwell KL; Davidson AR
    Nature; 2015 Oct; 526(7571):136-9. PubMed ID: 26416740
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-CRISPRs: Protein Inhibitors of CRISPR-Cas Systems.
    Davidson AR; Lu WT; Stanley SY; Wang J; Mejdani M; Trost CN; Hicks BT; Lee J; Sontheimer EJ
    Annu Rev Biochem; 2020 Jun; 89():309-332. PubMed ID: 32186918
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phage Against the Machine: Discovery and Mechanism of Type V Anti-CRISPRs.
    Marino ND
    J Mol Biol; 2023 Apr; 435(7):168054. PubMed ID: 36934807
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recruitment of CRISPR-Cas systems by Tn7-like transposons.
    Peters JE; Makarova KS; Shmakov S; Koonin EV
    Proc Natl Acad Sci U S A; 2017 Aug; 114(35):E7358-E7366. PubMed ID: 28811374
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CRISPR-Cas in mobile genetic elements: counter-defence and beyond.
    Faure G; Shmakov SA; Yan WX; Cheng DR; Scott DA; Peters JE; Makarova KS; Koonin EV
    Nat Rev Microbiol; 2019 Aug; 17(8):513-525. PubMed ID: 31165781
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A jumbo phage that forms a nucleus-like structure evades CRISPR-Cas DNA targeting but is vulnerable to type III RNA-based immunity.
    Malone LM; Warring SL; Jackson SA; Warnecke C; Gardner PP; Gumy LF; Fineran PC
    Nat Microbiol; 2020 Jan; 5(1):48-55. PubMed ID: 31819217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Discovery, Mechanisms, and Evolutionary Impact of Anti-CRISPRs.
    Borges AL; Davidson AR; Bondy-Denomy J
    Annu Rev Virol; 2017 Sep; 4(1):37-59. PubMed ID: 28749735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dynamics of CRISPR-mediated virus-host interactions in the human gut microbiome.
    López-Beltrán A; Botelho J; Iranzo J
    ISME J; 2024 Jan; 18(1):. PubMed ID: 39023219
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conditional tolerance of temperate phages via transcription-dependent CRISPR-Cas targeting.
    Goldberg GW; Jiang W; Bikard D; Marraffini LA
    Nature; 2014 Oct; 514(7524):633-7. PubMed ID: 25174707
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CRISPR-Cas systems in bacteria and archaea: versatile small RNAs for adaptive defense and regulation.
    Bhaya D; Davison M; Barrangou R
    Annu Rev Genet; 2011; 45():273-97. PubMed ID: 22060043
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CRISPR-Cas systems target a diverse collection of invasive mobile genetic elements in human microbiomes.
    Zhang Q; Rho M; Tang H; Doak TG; Ye Y
    Genome Biol; 2013 Apr; 14(4):R40. PubMed ID: 23628424
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cas13-induced cellular dormancy prevents the rise of CRISPR-resistant bacteriophage.
    Meeske AJ; Nakandakari-Higa S; Marraffini LA
    Nature; 2019 Jun; 570(7760):241-245. PubMed ID: 31142834
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanistic insights into the inhibition of the CRISPR-Cas surveillance complex by anti-CRISPR protein AcrIF13.
    Wang H; Gao T; Zhou Y; Ren J; Guo J; Zeng J; Xiao Y; Zhang Y; Feng Y
    J Biol Chem; 2022 Mar; 298(3):101636. PubMed ID: 35085557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How bacteria control the CRISPR-Cas arsenal.
    Leon LM; Mendoza SD; Bondy-Denomy J
    Curr Opin Microbiol; 2018 Apr; 42():87-95. PubMed ID: 29169146
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Roles of bacteriophages, plasmids and CRISPR immunity in microbial community dynamics revealed using time-series integrated meta-omics.
    Martínez Arbas S; Narayanasamy S; Herold M; Lebrun LA; Hoopmann MR; Li S; Lam TJ; Kunath BJ; Hicks ND; Liu CM; Price LB; Laczny CC; Gillece JD; Schupp JM; Keim PS; Moritz RL; Faust K; Tang H; Ye Y; Skupin A; May P; Muller EEL; Wilmes P
    Nat Microbiol; 2021 Jan; 6(1):123-135. PubMed ID: 33139880
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An anti-CRISPR that pulls apart a CRISPR-Cas complex.
    Trost CN; Yang J; Garcia B; Hidalgo-Reyes Y; Fung BCM; Wang J; Lu WT; Maxwell KL; Wang Y; Davidson AR
    Nature; 2024 Aug; 632(8024):375-382. PubMed ID: 38961300
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-CRISPR proteins: Counterattack of phages on bacterial defense (CRISPR/Cas) system.
    Chaudhary K; Chattopadhyay A; Pratap D
    J Cell Physiol; 2018 Jan; 233(1):57-59. PubMed ID: 28247934
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization and applications of Type I CRISPR-Cas systems.
    Hidalgo-Cantabrana C; Barrangou R
    Biochem Soc Trans; 2020 Feb; 48(1):15-23. PubMed ID: 31922192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structural and mechanistic insights into the CRISPR inhibition of AcrIF7.
    Kim I; Koo J; An SY; Hong S; Ka D; Kim EH; Bae E; Suh JY
    Nucleic Acids Res; 2020 Sep; 48(17):9959-9968. PubMed ID: 32810226
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lack of Cas13a inhibition by anti-CRISPR proteins from Leptotrichia prophages.
    Johnson MC; Hille LT; Kleinstiver BP; Meeske AJ; Bondy-Denomy J
    Mol Cell; 2022 Jun; 82(11):2161-2166.e3. PubMed ID: 35623354
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.